{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:24:19Z","timestamp":1787790259915,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Despite advances in mammography screening, some cancers remain undetected, prompting the evaluation of artificial intelligence (AI) as an independent third reader to reduce missed cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>In this prospective study, women eligible for the German Mammography Screening were enrolled at six sites belonging to one screening unit between August 2023 and February 2024. Each mammogram underwent double reading and was independently analyzed using Transpara, an AI-based detection software. Cases rated BI-RADS 4 or 5 by any reader or given a risk score of 10 by the software were reviewed in a consensus conference. Endpoints included: primary\u2014cancer detection rate (CDR) and positive predictive values (PPV); secondary\u2014analysis of cancers detected only by the software or missed by it.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      15,356 female participants (mean age 58.6\u2009\u00b1\u20095.6 years) were included. Overall, 115 breast cancers were detected (CDR triple reading: 0.75%; 95% CI: 0.62%, 0.90%). CDR of double reading and standalone AI was 0.68% (95% CI: 0.56, 0.83%) and 0.66% (95% CI: 0.54, 0.81%). Using Transpara as a third reader increased the detection rate by 9.5% (95% CI: 4.7%, 16.8%) compared to double reading (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). The PPV for consensus-conference referrals was 5.1% (95% CI: 4.2%, 6.1%), lower than double reading 7.5%(95% CI: 6.2%, 9.0%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). For recalled cases, the PPV was 13.7%(95% CI: 11.5%, 16.2%) versus 15.2% (95% CI: 12.6%, 18.1%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). All nine invasive cancers detected solely by AI were Luminal-A-like cancers. Among 13 cancers missed by the software, four were triple-negative.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adding Transpara as an independent third reader improved detection rates, mainly by identifying additional Luminal-A-like cancers, and increased the workload to the consensus conference and the number of recalled cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Question<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Does the integration of AI software as an independent third reader improve cancer detection rates in mammography screening without increasing false-positive findings and recall rates?<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Findings<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>AI as an independent third reader increased cancer detection by 9.5%, mainly identifying Luminal-A-like cancers, significantly decreasing the positive predictive values of cases referred to at the consensus conference and increasing the number of recalled cases.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Clinical relevance<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Using AI as an independent third reader enhances mammographic cancer detection by offering radiologists complementary sensitivity, especially for low-risk lesions. However, maintaining human readers is essential, as AI may miss aggressive subtypes like triple-negative breast cancers.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-026-12359-0","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T14:47:55Z","timestamp":1770302875000},"page":"4478-4488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["AI software as a third reader in breast cancer screening\u2014a prospective diagnostic observational study"],"prefix":"10.1007","volume":"36","author":[{"given":"Thomas","family":"Lehnen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Polenske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Daria","family":"Wichtmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9506-1452","authenticated-orcid":false,"given":"Nils Christian","family":"Lehnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"12359_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H et al (2022) Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 66:15\u201323","journal-title":"Breast"},{"key":"12359_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-023-02253-5","volume":"10","author":"Y Xu","year":"2023","unstructured":"Xu Y, Gong M, Wang Y, Yang Y, Liu S, Zeng Q (2023) Global trends and forecasts of breast cancer incidence and deaths. Sci Data 10:334","journal-title":"Sci Data"},{"key":"12359_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ijc.32767","volume":"147","author":"A Katalinic","year":"2020","unstructured":"Katalinic A, Eisemann N, Kraywinkel K, Noftz MR, H\u00fcbner J (2020) Breast cancer incidence and mortality before and after implementation of the German mammography screening program. Int J Cancer 147:709\u2013718","journal-title":"Int J Cancer"},{"key":"12359_CR4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00117-024-01283-3","volume":"64","author":"S Weigel","year":"2024","unstructured":"Weigel S, Katalinic A (2024) Strukturierte fr\u00fcherkennung des sporadischen mammakarzinoms. Radiologie 64:463\u2013470","journal-title":"Radiologie"},{"key":"12359_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11378-0","volume":"23","author":"F Heinze","year":"2023","unstructured":"Heinze F, Czwikla J, Heinig M, Langner I, Haug U (2023) German mammography screening program: program sensitivity between 2010 and 2016 estimated based on German health claims data. BMC Cancer 23:852","journal-title":"BMC Cancer"},{"key":"12359_CR6","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1007\/s00330-024-10681-z","volume":"34","author":"MB Bergan","year":"2024","unstructured":"Bergan MB, Larsen M, Moshina N et al (2024) AI performance by mammographic density in a retrospective cohort study of 99,489 participants in BreastScreen Norway. Eur Radiol 34:6298\u20136308","journal-title":"Eur Radiol"},{"key":"12359_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1148\/radiol.210948","volume":"304","author":"AD Lauritzen","year":"2022","unstructured":"Lauritzen AD, Rodr\u00edguez-Ruiz A, von Euler-Chelpin MC et al (2022) An artificial intelligence-based mammography screening protocol for breast cancer: outcome and radiologist workload. Radiology 304:41\u201349","journal-title":"Radiology"},{"key":"12359_CR8","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2589-7500(24)00267-X","volume":"7","author":"V Hernstr\u00f6m","year":"2025","unstructured":"Hernstr\u00f6m V, Josefsson V, Sartor H et al (2025) Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study. Lancet Digit Health 7:e175\u2013e183","journal-title":"Lancet Digit Health"},{"key":"12359_CR9","doi-asserted-by":"publisher","first-page":"e703","DOI":"10.1016\/S2589-7500(23)00153-X","volume":"5","author":"K Dembrower","year":"2023","unstructured":"Dembrower K, Crippa A, Col\u00f3n E, Eklund M, Strand F (2023) Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study. Lancet Digit Health 5:e703\u2013e711","journal-title":"Lancet Digit Health"},{"key":"12359_CR10","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1038\/s41591-023-02625-9","volume":"29","author":"AY Ng","year":"2023","unstructured":"Ng AY, Oberije CJG, Ambr\u00f3zay \u00c9 et al (2023) Prospective implementation of AI-assisted screen reading to improve early detection of breast cancer. Nat Med 29:3044\u20133049","journal-title":"Nat Med"},{"key":"12359_CR11","unstructured":"Screenpoint (2022) ScreenPoint Transpara User Manual: Softwareversion 1.7.3, SPM-MGR-009-014, Version B"},{"key":"12359_CR12","unstructured":"D\u2019Orsi CJ, Sickles EA, Mendelson EB et al (2013) ACR BI-RADS\u00ae Atlas, Breast Imaging Reporting and Data System, 5th edn American College of Radiology, Reston, VA"},{"key":"12359_CR13","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","volume":"32","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Curigliano G, Th\u00fcrlimann B et al (2021) Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 32:1216\u20131235","journal-title":"Ann Oncol"},{"key":"12359_CR14","doi-asserted-by":"publisher","unstructured":"Stock C, Hielscher T, Discacciati A (2024) DTComPair: comparison of binary diagnostic tests in a paired study design. R package version 1.2.6. https:\/\/doi.org\/10.32614\/CRAN.package.DTComPair","DOI":"10.32614\/CRAN.package.DTComPair"},{"key":"12359_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-020-00988-y","volume":"20","author":"JA Rold\u00e1n-Nofuentes","year":"2020","unstructured":"Rold\u00e1n-Nofuentes JA (2020) Compbdt: an R program to compare two binary diagnostic tests subject to a paired design. BMC Med Res Methodol 20:143","journal-title":"BMC Med Res Methodol"},{"key":"12359_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A et al (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12:77","journal-title":"BMC Bioinformatics"},{"key":"12359_CR17","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1007\/s00330-023-09461-y","volume":"33","author":"HW Koch","year":"2023","unstructured":"Koch HW, Larsen M, Bartsch H, Kurz KD, Hofvind S (2023) Artificial intelligence in BreastScreen Norway: a retrospective analysis of a cancer-enriched sample including 1254 breast cancer cases. Eur Radiol 33:3735\u20133743","journal-title":"Eur Radiol"},{"key":"12359_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77053-7","volume":"10","author":"L Sturesdotter","year":"2020","unstructured":"Sturesdotter L, Sandsveden M, Johnson K, Larsson A-M, Zackrisson S, Sartor H (2020) Mammographic tumour appearance is related to clinicopathological factors and surrogate molecular breast cancer subtype. Sci Rep 10:20814","journal-title":"Sci Rep"},{"key":"12359_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1148\/radiographics.13.4.8356272","volume":"13","author":"T Franquet","year":"1993","unstructured":"Franquet T, Miguel C, de, Cozcolluela R, Donoso L (1993) Spiculated lesions of the breast: mammographic-pathologic correlation. Radiographics 13:841\u2013852","journal-title":"Radiographics"},{"key":"12359_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1634\/theoncologist.2013-0380","volume":"18","author":"M Boisserie-Lacroix","year":"2013","unstructured":"Boisserie-Lacroix M, Macgrogan G, Debled M et al (2013) Triple-negative breast cancers: associations between imaging and pathological findings for triple-negative tumors compared with hormone receptor-positive\/human epidermal growth factor receptor-2-negative breast cancers. Oncologist 18:802\u2013811","journal-title":"Oncologist"},{"key":"12359_CR21","doi-asserted-by":"publisher","first-page":"vi23","DOI":"10.1093\/annonc\/mds191","volume":"23","author":"BE Dogan","year":"2012","unstructured":"Dogan BE, Turnbull LW (2012) Imaging of triple-negative breast cancer. Ann Oncol 23:vi23\u2013vi29","journal-title":"Ann Oncol"},{"key":"12359_CR22","doi-asserted-by":"publisher","first-page":"20130496","DOI":"10.1259\/bjr.20130496","volume":"87","author":"B Gao","year":"2014","unstructured":"Gao B, Zhang H, Zhang S-D et al (2014) Mammographic and clinicopathological features of triple-negative breast cancer. Br J Radiol 87:20130496","journal-title":"Br J Radiol"},{"key":"12359_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2022.06.027","volume":"173","author":"L Ding","year":"2022","unstructured":"Ding L, Poelhekken K, Greuter MJW et al (2022) Overdiagnosis of invasive breast cancer in population-based breast cancer screening: a short- and long-term perspective. Eur J Cancer 173:1\u20139","journal-title":"Eur J Cancer"},{"key":"12359_CR24","doi-asserted-by":"crossref","unstructured":"Wang X, Tan T, Gao Y et al (2023) DisAsymNet: disentanglement of asymmetrical abnormality on bilateral mammograms using self-adversarial learning. arXiv:2307.02935. https:\/\/arxiv.org\/pdf\/2307.02935","DOI":"10.1007\/978-3-031-43990-2_6"},{"key":"12359_CR25","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1002\/mp.15598","volume":"49","author":"J Bai","year":"2022","unstructured":"Bai J, Jin A, Wang T, Yang C, Nabavi S (2022) Feature fusion Siamese network for breast cancer detection comparing current and prior mammograms. Med Phys 49:3654\u20133669","journal-title":"Med Phys"},{"key":"12359_CR26","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41591-024-03408-6","volume":"31","author":"N Eisemann","year":"2025","unstructured":"Eisemann N, Bunk S, Mukama T et al (2025) Nationwide real-world implementation of AI for cancer detection in population-based mammography screening. Nat Med 31:917\u2013924","journal-title":"Nat Med"},{"key":"12359_CR27","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S1470-2045(23)00298-X","volume":"24","author":"K L\u00e5ng","year":"2023","unstructured":"L\u00e5ng K, Josefsson V, Larsson A-M et al (2023) Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study. Lancet Oncol 24:936\u2013944","journal-title":"Lancet Oncol"},{"key":"12359_CR28","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222176","volume":"307","author":"T Dratsch","year":"2023","unstructured":"Dratsch T, Chen X, Rezazade Mehrizi M et al (2023) Automation bias in mammography: the impact of artificial intelligence BI-RADS suggestions on reader performance. Radiology 307:e222176","journal-title":"Radiology"},{"key":"12359_CR29","doi-asserted-by":"publisher","first-page":"300060523119546","DOI":"10.1177\/03000605231195468","volume":"51","author":"W Li","year":"2023","unstructured":"Li W, Lu N, Chen C, Lu X (2023) Identifying the optimal cutoff point of Ki-67 in breast cancer: a single-center experience. J Int Med Res 51:3000605231195468","journal-title":"J Int Med Res"},{"key":"12359_CR30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10549-015-3559-0","volume":"153","author":"F Petrelli","year":"2015","unstructured":"Petrelli F, Viale G, Cabiddu M, Barni S (2015) Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat 153:477\u2013491","journal-title":"Breast Cancer Res Treat"},{"key":"12359_CR31","first-page":"117","volume":"16","author":"Q Ma","year":"2024","unstructured":"Ma Q, Liu Y-B, She T, Liu X-L (2024) The role of Ki-67 in HR+\/HER2- breast cancer: a real-world study of 956 patients. Breast Cancer (Dove Med Press) 16:117\u2013126","journal-title":"Breast Cancer (Dove Med Press)"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12359-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-026-12359-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12359-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T12:25:47Z","timestamp":1779798347000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-026-12359-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["12359"],"URL":"https:\/\/doi.org\/10.1007\/s00330-026-12359-0","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"1 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Dr. Nils Christian Lehnen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"There is no overlap of study subjects or cohorts with other publications.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}